Eyeworld

EW MEETING REPORTER 78 June 2017 Reporting from OIS@ASCRS, May 4, 2017 Los Angeles said, and they are created to be used specifically in the eye. There are a number of factors in the current innovation process that are helping to speed it up, including the FDA, commercialization, and strategics. However, he also noted that current challenges include con- strained early stage funding, regula- tory and reimbursement uncertainty, and a small ecosystem of strategics. Dr. Kliman recognized several areas that he thinks are future opportuni- ties, including presbyopia, less inva- sive refractive surgery, and myopia stabilization/prevention. Following Dr. Kliman's opening remarks, two ophthalmology inno- vation showcases featured presen- tations from 21 companies: Aerie Pharmaceuticals (Irvine, California), Ocular Therapeutix (Bedford, Massa- chusetts), Mati Therapeutics (Austin, Texas), InnFocus (Miami), Ivantis (Irvine, California), EyeGate Pharma (Waltham, Massachusetts), Cassini (The Hague, the Netherlands), LacriScience (Washington, D.C.), Kala Pharmaceuticals (Waltham, Massachusetts), SightGlass Vision Dr. Kliman discussed the inno- vation cycle to show how things move from the beginning of the in- vention all the way to commercial- ization. "This process is not easy and often feels like a lottery," he said. Dr. Kliman highlighted a number of companies presenting at this year's OIS meeting who started at an early stage in the cycle and have emerged. "We are in an amazing era of inno- vation," Dr. Kliman said. It hasn't always been that way. However, he said that now it seems that innova- tion has changed and gotten faster and more elegant. The first inno- vation in ophthalmology was the invention of spectacles in the 13th century. It took 600 years to move from that to a lens that could be put on the eye in the late 19th century, Dr. Kliman said. In the 20th century, there were more innovations, in- cluding IOLs and the excimer laser. More recently, in the first 17 years of the millennium, there have been a number of important innovations, including the femtosecond laser, corneal inlays, and MIGS. "These are first-of-a-kind innovations," he T he Ophthalmology Innova- tion Summit (OIS) kicked off with an anterior seg- ment update from Gilbert Kliman, MD, Menlo Park, California, one of the chairmen of the meeting. At this year's meeting, 21 companies were scheduled to present, he said, with additional interactive panels and other pro- gramming. "A key thing about this meet- ing is that we want to make it more interactive," he said. This includes giving attendees the ability to participate and vote on audience questions as well as rate company presentations by using the OIS app. "I've never been more excited than right now for major inno- vations happening throughout ophthalmology, particularly in the anterior segment," Dr. Kliman said, adding that there is a changing stan- dard of care around the world. He highlighted a number of new tech- nology categories, including MIGS, femtosecond lasers, IOLs, corneal inlays, corneal crosslinking, and dry eye inventions. Reporting from OIS@ASCRS Sponsored by

• Blank Page
• Blank Page (1)